



# Be the pioneer and join the ABC1000 Program

Try out the novel ABC Scores to assess the stroke and  
bleeding risks for your atrial fibrillation patients

## ABC Scores combine biomarkers with classic risk factors for better stroke and bleeding risk prediction<sup>1-5</sup>



ABC stroke and bleeding scores are **personalized stroke and bleeding risk assessment scores** that estimate risk of stroke/systemic embolic events and bleeding in patients with atrial fibrillation.



ABC Scores have **better prognostic performance** vs. standard of care (CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED) as they have **better discriminative ability** and net reclassification benefit validated and calibrated in over **37,000** patients from six major pharmaceutical trials. This is expressed by improved C-statistics of ABC scores vs. standard of care risk tools.<sup>1-5</sup>



Patient outcomes (clinical utility) and economic utility data for ABC Scores is **currently in generation** with the prospective, interventional, randomized clinical trial called ABC-AF<sup>6</sup>. Results will be published in **2026**.

**What are ABC Scores?**

- Age**
- Biomarkers<sup>b</sup>**
  - Elecsys<sup>®</sup> GDF-15
  - Elecsys<sup>®</sup> NT-proBNP
  - Elecsys<sup>®</sup> cTnT-hs
  - Hemoglobin<sup>c</sup>
- Clinical history**

## What is ABC1000?

ABC1000 is a commercial product evaluation program<sup>a</sup> offered to physicians who diagnose and treat atrial fibrillation patients and would like to try the novel **ABC Stroke and ABC Bleeding scores** to risk stratify their atrial fibrillation patients.

ABC Scores      ABC1000      Number of patient cases evaluated in the program

<sup>a</sup> This product evaluation program is applicable only in countries where Elecsys<sup>®</sup> GDF-15, Elecsys<sup>®</sup> NT-proBNP and Elecsys<sup>®</sup> cTnT-hs have regulatory approval as this is a commercial program.  
<sup>b</sup> All of these biomarkers have been CE marked.  
<sup>c</sup> Hemoglobin is not included in the free-of-charge kits package provided by Roche.

## What are the benefits of joining the program?



### Physicians

- Access to a superior and innovative risk assessment tool<sup>1-5</sup>
- Chance to optimize treatment for patients
- Potential decrease in patient adverse events<sup>6</sup>
- Join a network of innovators in the cardiac biomarkers field



### Patients

- Access to a personalized risk assessment tool
- More accurate predication of stroke and bleeding risk<sup>1,3</sup>
- Treatment optimization to individual risk
- Potential decrease in adverse events like stroke, bleeding and death<sup>6</sup>



### Labs

- Access to the new biomarker GDF-15
- Positioning as 'innovators' with supply of GDF-15
- Differentiating factor from the other labs



Participation in the ABC1000 Program is voluntary and you are free to opt out at any moment!



## Be the pioneer in treating atrial fibrillation patients

Access to an innovative solution is just a few steps away:



### 1 Online registration

Register with the **QR code**. After receiving a confirmation that the country you reside in is a part of the ABC1000 Program, a Roche representative will contact you about the next steps and start the contracting process.



Scan to register



### 2 Contract and biomarker kits

Once the contract is signed, you (or your laboratory partner, depending on the contract agreement) will receive **2+ kits** (i.e.  $\geq 200$  tests)<sup>d</sup> of each of the biomarkers: Elecsys® GDF-15, Elecsys® NT-proBNP, and Elecsys® cTnT-hs together with all necessary calibration and quality control reagents.



### 3 Try it out!

Use the biomarker kits in your daily practice and determine the personalized ABC Stroke and ABC Bleeding risk scores for your patients using publicly available risk calculators online.



### 4 Tell us what you think

How easy was it to use the ABC Scores? Complete the online Evaluation Survey where you can share your experience (you will receive the link and login to the survey per email).

The Evaluation Survey aims to collect your **feedback regarding your personal experience and satisfaction** with ABC Scores. No patient data will be collected.

<sup>d</sup> The precise number of kits you will receive depends on the local Roche compliance guidance and can differ between countries.


## What happens next?



The program will close, once feedback for approximately 1,000 patients is collected. Roche Diagnostics will analyze the submitted surveys and publish a **white paper** with the consolidated results<sup>e</sup>.

## Outcomes of the ABC1000 Program

Other tentative follow-up initiatives of the ABC1000 Program, include the possibility to share your experience with ABC Scores and the white paper at educational events and congresses, participation in a commercial advisory board with other contributing physicians to discuss the outcomes of the Program<sup>f</sup>.



<sup>e</sup> Subject to change, depending on the quantity and quality of feedback submitted in the Evaluation Survey.

<sup>f</sup> Outcomes of the ABC1000 Program are subject to change depending on the success of the program.

## References

1. Hijazi, Z. Lancet (2016); 387(10035):2302-2311
2. Hijazi, Z. Eur Heart J (2016); 37(20):1582-1590
3. Berg, D.D. Circulation (2019); 139(6):760-771
4. Oyama, K. Eur Heart J (2021); 42(17):1698-1706
5. Benz, AP. Circulation (2021); 143(19):1863-1873
6. ClinicalTrials.gov NCT03753490 <https://clinicaltrials.gov/ct2/show/NCT03753490>

## Published by

Roche Diagnostics International Ltd  
6343 Rotkreuz, Switzerland

© 2022 All trademarks mentioned enjoy legal protection

Elecsys is a trademark of Roche. All trademarks and brand names are the property of their respective owners. All company, product and service names used in this brochure are for identification purposes only. Use of these names, logos and brands does not imply endorsement.

[diagnostics.roche.com](https://diagnostics.roche.com)